Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Patients With Breast Cancer
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Search/Filter
Loading...
Black and White Women Who Received Neoadjuvant Therapy Were Equally Likely to Have Pathologic Complete Response
Tumor biology, not race, was a more significant factor in predicting response to clinical trial treatment SAN ANTONIO – Analysis...
Black Women are More Likely to Develop Lymphedema Following Breast Cancer Treatment than White Women
SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was...
Elacestrant May Improve Outcomes for Patients Whose Metastatic Breast Cancers Progressed on Prior Endocrine Therapy
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Single-cell Spatial Analysis May Help Predict Response to Neoadjuvant Immunotherapy in Triple-negative Breast Cancer
Imaging mass cytometry was feasible in a large clinical trial of atezolizumab in combination with chemotherapy SAN ANTONIO –...
Using Genomics to Match Treatments Improved Outcomes for Certain Patients With Metastatic Breast Cancer
The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) was highly predictive of the benefits of targeted therapies...
A Peptide-drug Conjugate that Targets the Acidic Environment of Cancer Cells May Improve the Efficacy of Immunotherapy
PHILADELPHIA – A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint...
Inhibition of the Aurora Kinase A Protein May Help Overcome Lung Cancer Resistance to KRAS Inhibition
PHILADELPHIA – In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a...
Adding ErbB Tyrosine Kinase Inhibitor to KRAS Inhibitor May Help Circumvent Lung Cancer Resistance to Prior Therapies
PHILADELPHIA – Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinaseinhibitor, was feasible in treating...
DNA Alkylation Drug May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors
PHILADELPHIA – In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young...